GLP-1s Cut MACE Risk 13% in 90,000-Patient Review
ARU's meta-analysis of 11 cardiovascular outcome trials finds GLP-1 receptor agonists reduce major adverse cardiovascular events by 13% over roughly 3 years.
May 22, 2026 · 3 min read
A large meta-analysis from Anglia Ruskin University has quantified what the individual cardiovascular outcome trials have been pointing toward: across more than 90,000 patients and 11 major trials, GLP-1 receptor agonists reduced the risk of major adverse cardiovascular events (MACE) — heart attack, stroke, and cardiovascular death — by approximately 13% compared with placebo over an average follow-up of nearly three years.
What the Review Covered
Lead researcher Dr. Simon Cork at ARU's School of Medicine assembled data from 11 large-scale cardiovascular outcome trials (CVOTs) involving over 90,000 participants. The review limited its scope to trials with a minimum one-year follow-up, specifically to capture longer-term effects rather than near-term biochemical changes.
The CVOTs included trials spanning the major approved GLP-1 agents — including the SELECT trial (semaglutide), the LEADER and SUSTAIN-6 trials (liraglutide and semaglutide respectively), and others — making this one of the broadest class-level analyses published.
The summary estimate of a 13% reduction in MACE applies to the class as a whole. Individual trials varied around that figure depending on the population studied (primary vs. secondary prevention, diabetes vs. no diabetes, baseline cardiovascular risk) and the drug studied.
Why It Matters Beyond Diabetes
The significance of this review extends beyond confirming what cardiologists and endocrinologists already knew from individual trials. Several points are clinically relevant:
The class-level signal is robust. Pooling 90,000+ patients across 11 trials with similar endpoints produces a more stable estimate than any single trial could. A 13% relative reduction in MACE is a meaningful effect in cardiovascular medicine — comparable to the benefit seen with some statin intensification strategies.
The benefit appears in populations without diabetes. The SELECT trial demonstrated cardiovascular benefit in adults with established cardiovascular disease and overweight or obesity but without type 2 diabetes. The meta-analysis context is important here: for most of the CVOT history, the enrolled populations had diabetes, so the class-wide cardiovascular signal was assumed to require that metabolic context. SELECT and the broader review data suggest otherwise.
Minimum one-year follow-up was required. The researchers were specifically interested in durable effects, not early changes in biomarkers. The three-year average follow-up captures sustained risk reduction, not just the acute phase.
What This Doesn't Establish
The 13% MACE reduction is a class-wide estimate — it doesn't tell prescribers which agent is best for cardiovascular protection, in which population, or at which dose. The trials included in the review varied in how they selected participants, their era of conduct (which affects background treatment), and the specific agents studied.
The review also can't resolve the mechanistic question: how much of the cardiovascular benefit is mediated by weight loss, how much by glycemic improvement, and how much by direct drug effects on cardiac and vascular tissue. All three pathways are plausible; isolating them requires study designs beyond standard CVOTs.
What to Watch
Tirzepatide's cardiovascular outcomes trial data — from SURPASS-CVOT and SURMOUNT-4 cardiac substudy — adds to this picture but wasn't fully incorporated into the ARU review. The emerging data on retatrutide, including the cardiovascular sub-study components of the TRIUMPH program, will eventually extend this meta-analysis landscape further. Whether the glucagon receptor component in retatrutide adds cardiovascular benefit above GLP-1/GIP agonism is an active research question.
For now, the ARU review provides the clearest class-level summary of the cardiovascular case for GLP-1 receptor agonists: a consistent, durable, ~13% reduction in major events across a large and heterogeneous patient base.
Sources
Sources